Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“Follow MedCity News if you want to know who is doing what in healthcare innovation - and whether it's working or not.”

Chris Seper, CEO & Founder, MedCityNews.com


Sign up for our daily newsletter


Drug companies pay Ohio $8.44 million in Medicaid billing suit

12:21 pm by | 0 Comments

Photo illustration courtesy of Flickr user Vizzzual.comAbbott Laboratories, Pharmacia,  Roxane Laboratories and Warrick Pharmaceuticals have paid Ohio $8.44 million to settle a five-year-old suit over misleading drug prices.

The state had accused the four companies of fraud, unjust enrichment and violating the Consumer Sales Practices and Deceptive Trade Practices Acts for reporting false and misleading information about their wholesale drug prices. That information resulted in higher costs for the state’s Medicaid Program, according to a release from the Ohio Attorney General’s Office.

For example, the attorney general’s office pointed out in 2004 that a respiratory medicine by Roxane was billed at 47 cents a unit when the wholesale price was closer to 11 cents a unit.

In the settlement, Abbott paid $1.34 million, Pharmacia paid $400,000, Roxane paid $2.4 million and Warrick paid $4.3 million. Drugmaker Dey was also part of the earlier suit. It settled in 2006 for $2.9 million cash and $1.1 million in donated pharmaceuticals.

Ohio’s Attorney General Richard Cordray stated his office was “sending the message that we will insist on fair and honest drug pricing.”

[Photo courtesy of Flickr user Vizzzual.com]

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Chris Seper

By Chris Seper MedCity News

Chris Seper is the CEO at MedCity Media, which publishes MedCityNews.com. He is also a senior writer at MedCity News. Reach him at [email protected]
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement